Development · 26 Aug 2026
CIPLA, full dossier2 publishers have reported this development. Each act of reporting is below, cited.
Cipla's Pithampur manufacturing facility received seven observations from the USFDA in a follow-up inspection conducted between August 17 and August 25, 2026.
Cipla received seven observations from the USFDA following a follow-up inspection of its Pithampur manufacturing facility conducted from August 17 to August 25, 2026.
USFDA issued Form 483 with seven inspectional observations to Cipla's Pithampur manufacturing facility following a cGMP inspection conducted from August 17-25, 2026.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.